Ghaith Noaiseh, MD

Professional Background

Training:

Fellowship Rheumatology
07/2010 – 06/2012 University of Pennsylvania, Philadelphia, Pennsylvania

Residency and Chief residency Internal Medicine
07/2005 – 06/2007 Case Western Reserve University/St. Vincent Charity Hospital, Cleveland, Ohio

Internship Internal Medicine
06/2004 – 06/2005 Case Western Reserve University/St. Vincent Charity Hospital, Cleveland, Ohio

Internship Laboratory Medicine
10/2002 – 07/2003 Tishreen University Hospital, Lattakia, Syria

Research Focus:

1. Epidemiology, clinical spectrum and management of Neurological and Vasculitic manifestations of Sjogren’s Disease.
2. Clinical trials in Sjogren’s Disease and Systemic Lupus erythematosus.

Clinical Interests:

Management of complex Sjogren’s Disease patients
Systemic lupus erythematosus

After completing his Internal Medicine residency, Dr. Ghaith Noaiseh joined the Cleveland Clinic, where he served as an academic hospitalist from 2007 to 2010. In 2012, he joined the faculty at the University of Pittsburgh, where he worked within the UPMC Lupus Center of Excellence and later established the UPMC Sjögren’s Clinic in 2014. During his time in Pittsburgh, he led and participated in numerous NIH- and industry-sponsored clinical trials in Sjögren’s disease and systemic lupus erythematosus (SLE), and was involved with the Lupus Clinical Investigators Network (LuCIN), a major North American lupus clinical trials consortium.
12Dr. Noaiseh currently directs the KU Sjögren’s Clinic in close collaboration with a multidisciplinary team of specialists in otolaryngology, ophthalmology, neurology, pulmonary medicine, and pathology at the University of Kansas. He is actively engaged in investigator-initiated research and multiple clinical trials in Sjögren’s disease and SLE, helping expand access to innovative therapies for patients with complex autoimmune disease. He also serves as Co-Lead of the Sjögren’s Foundation Clinical Practice Guidelines effort focused on central nervous system manifestations of Sjögren’s disease and is a member of the Sjogren’s Foundation Board of Directors.

• MD, Medicine , Tishreen University Faculty of Medicine , Lattakia, Syria
• Internship, Laboratory Medicine, Tishreen University Hospital , Lattakia, Syria
• Internship, Medicine , Case Western Reserve University/St. Vincent Charity Hospital, Cleveland, OH
• Residency, Internal Medicine, Case Western Reserve University/St. Vincent Charity Hospital, Cleveland , OH
• Clinical Fellowship, Rheumatology , University of Pennsylvania, Philadelphia, PA

• KUMC- Division of Rheumatology- Divisional research committee, Member, 2020 - Present

---

Research

Overview

Selected publications:

1. Noaiseh G, Sivils KL, Campbell K, Idokogi J, Lo KH, Liva SG, Leu JH, Dhatt H, Leonardo S, Hubbard JJ, Gottenberg JE. Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomized, phase 2, placebo-controlled, double-blind trial
Lancet. October 2025. PMID: 41284548

2. Fox R, Deboo A, Baker M, Danieldes S, Sousa ED, Frantsve-Hawley J, Goodman BP, Hammitt KM, King J, Makara M, Mandel S, Noaiseh G, Pavlakis P, Sarka G, Varadhachary A, Wallace D, Scofield H, Carteron N, Carsons S. Sjögren’s Foundation Clinical Practice Guidelines Expert Panel
Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations
Arthritis Care & Research (Hoboken) - 2025 PMID: 41327784

3. Noaiseh G, Deboo A, King J, Varadhachary A, Sarka G, Goodman BP, Frantsve-Hawley J, Hammitt KM, Fox R, Baker M, Danieldes S, Sousa ED, Mandel S, Pavlakis P, Scofield H, Wallace D, Carteron N, Carsons S. Sjögren’s Foundation Clinical Practice Guidelines Expert Panel
Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology Arthritis and Rheumatology.2025. PMID: 39489692

4. Noaiseh G, Baer AN.
Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach.
Best Pract Res Clin Rheumatol. 2020 Feb. PMID: 32005417

5. James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW.
Unique Sjögren's syndrome patient subsets defined by molecular features.
Rheumatology (Oxford). 2020 Apr 1. PMID: 31497844